SYDNEY (Reuters) - Australia's CSL, the world's largest producer of blood plasma products, is trialling "dynamic pricing" of payments to donors to grow profit margins amid persistently high supply ...

CSL Plasma has satisfied terms of a court agreement to prevent discriminatory screening of donors based on gender identity, the Minnesota Department of Human Rights announced Tuesday. The progress ...

Pharmaceuticals company CSL on Tuesday reported a 3% rise in first-half profit, benefiting from further growth in its main blood-plasma business. Australia-based CSL, which runs a network of ...

CSL shares are currently trading near a 7-year low. CSL shares have been under pressure, trading near $180, due to softer profits, rising costs, and slow plasma business recovery. Despite recent ...

Nov 18 (Reuters) - Australian biotech firm CSL (CSL.AX), opens new tab said on Tuesday it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, in a move to expand its ...

CSL is one of three tier one plasma therapy companies who benefit from an oligopoly in this highly consolidated market. All the players are vertically integrated as plasma sourcing is the most ...

Blood plasma donation, similar to blood donation, is voluntary in most countries, but in recent years Germany, Austria, the Czech Republic and Hungary have followed the US in allowing plasma donors to ...